Glucocorticoid Replacement and Mortality in Patients with Nonfunctioning Pituitary Adenoma | Zendy

Thomas Zueger | Zendy; Paul Kirchner | Zendy; Coline Herren | Zendy; Stefan Fischli | Zendy; Marcel Zwahlen | Zendy; Emanuel Christ | Zendy; Christoph Stettler | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Glucocorticoid Replacement and Mortality in Patients with Nonfunctioning Pituitary Adenoma

Author(s) -

Thomas Zueger,

Paul Kirchner,

Coline Herren,

Stefan Fischli,

Marcel Zwahlen,

Emanuel Christ,

Christoph Stettler

Publication year - 2012

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2012-2432

Subject(s) - hypopituitarism , medicine , pituitary adenoma , glucocorticoid , acromegaly , concomitant , hazard ratio , proportional hazards model , context (archaeology) , hydrocortisone , endocrinology , adenoma , hormone , growth hormone , biology , confidence interval , paleontology

Current treatment guidelines generally suggest using lower and weight-adjusted glucocorticoid replacement doses in patients with insufficiency of the hypothalamic-pituitary-adrenal (HPA) axis. Although data in patients with acromegaly revealed a positive association between glucocorticoid dose and mortality, no comparable results exist in patients with nonfunctioning pituitary adenomas (NFPA).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research